Dear Investors, We are pleased to announce the positive Phase 2 topline results for our ATH434-201 clinical trial. The trial achieved our target measures for success with a favorable safety profile and no drug-related serious adverse events. Strong clinical results were observed, with statistical significance reached on the UMSARS I rating scale and a reduction in iron content seen on biomarker endpoints. Our ATH434 drug candidate has shown promise as a potential disease-modifying therapy for Multiple System Atrophy (MSA), a rare and debilitating neurodegenerative disease with no approved treatment. The Phase 2 trial demonstrated exceptional results overall, including robust efficacy on key clinical endpoints and evidence of clinical benefit on secondary endpoints. We invite you to review the full details of the trial results and encourage you to reach out with any questions you may have. We are excited about the potential of ATH434 and look forward to advancing its development as a treatment for MSA. Sincerely, David and the team